CCO Management Series
Fine-Tuning Antiretroviral Therapy in HIV-Infected Patients With Virologic Suppression: Strategies to Address Toxicity, Convenience, and Quality of Life
Fine-Tuning Antiretroviral Therapy to Improve Regimen Convenience
|
Module 1 of 3
|
CME Program Director:
John P. Phair, MD
|
|
 Paul E. Sax, MD, describes antiretroviral switch strategies designed to improve the convenience of a virologically suppressive regimen. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe antiretroviral switch strategies designed to improve the convenience of a virologically suppressive regimen
- Discuss the results of clinical trials evaluating switches in antiretroviral therapy in patients with virologic suppression
- Identify potential risks associated with regimen modification in patients with virologic suppression
|
Modifying Antiretroviral Therapy to Manage or Prevent Adverse Effects
|
Module 2 of 3
|
CME Program Director:
John P. Phair, MD
|
|
Edwin DeJesus, MD, FACP, describes antiretroviral switch strategies designed to improve the tolerability of a virologically suppressive regimen. Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify toxicities associated with antiretroviral therapy
- Describe antiretroviral switch strategies designed to improve the tolerability of a virologically suppressive regimen
- Discuss the results of clinical trials evaluating switches in antiretroviral therapy in patients with virologic suppression
|
Evolving Strategies for Fine-Tuning Antiretroviral Therapy: Where Have We Been, Where Are We Going?
|
Module 3 of 3
|
CME Program Director:
John P. Phair, MD
|
|
William G. Powderly, MD, reviews historical trends in antiretroviral switch strategies and considers the lessons that may be applied to current clinical practice. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe antiretroviral switch strategies designed to improve the tolerability of a virologically suppressive regimen
- Discuss the results of clinical trials evaluating switches in antiretroviral therapy in patients with virologic suppression
- Identify potential risks associated with regimen modification in patients with virologic suppression
|
Interactive Case Challenges
A series of 3 interactive case challenges designed to explore clinical decision making regarding modification of antiretroviral therapy in patients with virologic suppression.
Management of a Virologically Suppressed Patient Experiencing Difficulty Adhering to His Initial NNRTI-Based Regimen
CME Program Director:
John P. Phair, MD
|
|
 Along with Paul Sax, MD, choose management strategies in a virologically suppressed patient who experiences difficulty adhering to therapy, including the use of regimen simplification and the selection of management strategies for treatment-emergent adverse events. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss strategies aimed at improving adherence in virologically suppressed patients
- Describe alternative regimens available for patients who experience difficulty adhering to some antiretroviral therapies
- Describe possible interventions aimed at improving adherence through the management of adverse events experienced by patients on antiretroviral therapy
|
A 36-Year-Old Male Patient With Virologic Suppression Experiencing Progressive Lipoatrophy
Program Director:
John P. Phair, MD
|
|
Join Edwin DeJesus, MD, FACP, in this interactive case challenge and test your treatment choices for a virologically suppressed patient who presents with worsening lipoatrophy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss strategies for the management of lipoatrophy in virologically suppressed patients
- Describe therapeutic options for HIV-infected patients experiencing adverse events with an otherwise successful regimen
- Discuss regimen simplification strategies aimed at improving patient convenience and quality of life while maintaining virologic suppression
|
A 48-Year-Old HIV-Infected Man With Hyperlipidemia on HAART
Program Director:
John P. Phair, MD
|
|
Follow William G. Powderly, MD, through an interactive case challenge on how to manage a patient with hyperlipidemia while on HAART. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss data on the risk of myocardial infarction and cardiovascular disease in HIV-infected patients on HAART
- Describe considerations for choosing a lipid-lowering agent to manage dyslipidemia in HIV-infected patients
- Outline data on the impact of regimen modification to manage dyslipidemia in patients on stable HAART
|
Interactive Tool
Fine-Tuning Antiretroviral Therapy
 |
|
Considering switching a virologically suppressive antiretroviral regimen and want to know the key data associated with the specific switch?
This tool enables you to select specific switches that have been evaluated in controlled studies and then view a convenient graphical summary of the key data from those studies. You can also print the data and/or download slides.
|
Slideset Module
Fine-Tuning Antiretroviral Therapy in HIV-Infected Patients With Virologic Suppression: Strategies to Address Toxicity, Convenience, and Quality of Life
|
|
|
A comprehensive illustrated guide to antiretroviral modification in HIV patients with virologic suppression, comprising slides and notes and developed with the aid of Paul E. Sax, MD. Learning Objectives
Upon completion of this activity, participants should be able to:
- List the various possible rationales for modifying antiretroviral therapy in patients with virologic suppression
- Discuss antiretroviral switch strategies designed to improve the convenience of a suppressive regimen
- Describe changes to antiretroviral therapy designed to prevent the development of adverse effects or to ameliorate toxicities that are already present
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|